Breast cancer: Early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging

Radiology

Volumn 272, Issue 2, 2014, Pages 385-396

  Cho, Nariya ^a   Im, Seock Ah ^a   Park, In Ae ^a   Lee, Kyung Hun ^a   Li, Mulan ^a   Han, Wonshik ^a   Noh, Dong Young ^a   Moon, Woo Kyung ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ENDOXANE; GADOBUTROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DYNAMIC CONTRAST MATERIAL NUCLEAR MAGNETIC RESONANCE IMAGING; EXTRACELLULAR SPACE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFORMED CONSENT; MASTECTOMY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PARAMETRIC RESPONSE MAP ANALYSIS; PARTIAL MASTECTOMY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CONTRAST MEDIA; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGANOMETALLIC COMPOUNDS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; TAXOIDS; TREATMENT OUTCOME;

EID: 84905053610     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14131332     Document Type: Article

References (32)

1. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26(5):778-785. (Pubitemid 351264391)
2. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19(22):4224-4237. (Pubitemid 33081640)
3. Kaufmann M, von Minckwitz G, Mamounas EP, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 2012;19(5):1508-1516.
4. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24(13):2019-2027. (Pubitemid 46622110)
5. Ah-See ML, Makris A, Taylor NJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2008;14(20):6580-6589.
6. Yu Y, Jiang Q, Miao Y, et al. Quantitative analysis of clinical dynamic contrast-enhanced MR imaging for evaluating treatment response in human breast cancer. Radiology 2010;257(1):47-55.
7. Li SP, Makris A, Beresford MJ, et al. Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy. Radiology 2011;260(1): 68-78.
8. Hylton NM, Blume JD, Bernreuter WK, et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy - results from ACRIN 6657/I-SPY TRIAL. Radiology 2012;263(3): 663-672.
9. Galbán CJ, Chenevert TL, Meyer CR, et al. The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med 2009;15(5):572-576.
10. Galbán CJ, Chenevert TL, Meyer CR, et al. Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res 2011;17(14): 4751-4760.
11. Bonekamp S, Jolepalem P, Lazo M, Gulsun MA, Kiraly AP, Kamel IR. Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data. Radiology 2011; 260(3):752-761.
12. Chou CP, Wu MT, Chang HT, et al. Monitoring breast cancer response to neoadjuvant systemic chemotherapy using parametric contrast-enhanced MRI: a pilot study. Acad Radiol 2007;14(5):561-573.
13. Keam B, Im SA, Kim HJ, et al. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 2009; 116(1):153-160.
14. Chatterji M, Mercado CL, Moy L. Optimizing 1.5-tesla and 3-tesla dynamic contrast-enhanced magnetic resonance imaging of the breasts. Magn Reson Imaging Clin N Am 2010; 18(2):207-224.
15. Grady L. Random walks for image segmentation. IEEE Trans Pattern Anal Mach Intell 2006;28(11):1768-1783. (Pubitemid 46405425)
16. Yi A, Cho N, Im SA, et al. Survival outcomes of breast cancer patients who receive neoadjuvant chemotherapy: association with dynamic contrast-enhanced MR imaging with computer-aided evaluation. Radiology 2013; 268(3):662-672.
17. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997;7(1):91-101. (Pubitemid 28365643)
18. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10(3): 223-232. (Pubitemid 29463104)
19. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005;40(11):715-724. (Pubitemid 41546838)
20. Fram EK, Herfkens RJ, Johnson GA, et al. Rapid calculation of T1 using variable flip angle gradient refocused imaging. Magn Reson Imaging 1987;5(3):201-208. (Pubitemid 17133355)
21. Orton MR, d'Arcy JA, Walker-Samuel S, et al. Computationally efficient vascular input function models for quantitative kinetic modelling using DCE-MRI. Phys Med Biol 2008; 53(5):1225-1239. (Pubitemid 351594423)
22. Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 2003;12(5):320-327. (Pubitemid 37322062)
23. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010;28(7): 1145-1153.
24. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25(1):118-145. (Pubitemid 350003059)
25. Faul F, Erdfelder E, Lang AG, Buchner AG. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39(2):175-191.
26. Guidelines from the National Cancer Institute Cancer Imaging Program MR Workshop on Translational Research in Cancer. http://dctd.cancer.gov/ ProgramPages/cip/clinical-trials-imaging.htm. Published 2004. Accessed May 7, 2013.
27. Marinovich ML, Sardanelli F, Ciatto S, et al. Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI. Breast 2012;21(5):669-677.
28. Padhani AR, Hayes C, Assersohn L, et al. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology 2006;239(2):361-374.
29. Koo HR, Cho N, Song IC, et al. Correlation of perfusion parameters on dynamic contrast-enhanced MRI with prognostic factors and subtypes of breast cancers. J Magn Reson Imaging 2012;36(1):145-151.
30. Esserman LJ, Berry DA, DeMichele A, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL - CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012;30(26):3242-3249.
31. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30(15): 1796-1804.
32. Bauknecht HC, Romano VC, Rogalla P, et al. Intra- and interobserver variability of linear and volumetric measurements of brain metastases using contrast-enhanced magnetic resonance imaging. Invest Radiol 2010;45(1): 49-56.